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The calcium ionophore ionomycin induces 
apoptosis-like events in the human 
embryonic kidney (HEK) cell line at early 
times. Plasma membrane blebbing, 
mitochondrial depolarization, external-
ization of phosphatidylserine and nuclear 
permeability changes can all be observed 
within 15 min of treatment. However, there 
is no activation of caspases or chromatin 
condensation. Expression of a fusion protein 
containing the enhanced green fluorescent 
protein (EGFP) and human cytosolic Group 
IVA phospholipase A2α (EGFP-cPLA2α) in 
these cells prevents the ionomycin-induced 
phosphatidylserine externalization and 
death. Cells expressing the cPLA2α mutant 
D43N, which does not bind calcium, retain 
their susceptibility to ionomycin-induced 
cell death. Both non-expressing and EGFP-
D43N-cPLA2α-expressing HEK cells can be 
spared from ionomycin-induced cell death 
by pretreating them with exogenous 
arachidonic acid. Moreover, during calcium 
overload, mitochondrial depolarization is 
significantly lower in the EGFP-cPLA2α-
expressing cells than in cells expressing 
normal amounts of cPLA2α. These results 
suggest that early cell death events 
promoted by an overload of calcium can be 
prevented by the presence of high levels of 
arachidonic acid. 
 
The phospholipase A2 (PLA2)1 superfamily 
constitutes a heterogeneous group of enzymes 
whose common feature is to hydrolyze the 
fatty acid at the sn-2 position of 
glycerophospholipids [1, 2]. Mammalian cells 
contain structurally diverse forms of PLA2s 
which, according to their biochemical 
characteristics, can be classified into three 
major families, namely the Ca2+-dependent 
secreted enzymes, the Ca2+-dependent 
cytosolic enzymes, and the Ca2+-independent 
cytosolic enzymes [1, 2]. The presence of 
PLA2 enzymes in all cells and tissues 
underscores their key role in a number of 
biochemical processes, including the 
mobilization of free arachidonic acid (AA), 
and the regulation of membrane phospholipid 
homeostasis via deacylation/reacylation 
reactions [1, 2]. 
 Among all the PLA2 forms, the 
cytosolic Group IVA phospholipase A2, also 
known as cytosolic phospholipase A2α 
(cPLA2α), exhibits a unique preference for the 
hydrolysis of glycerophospholipids that 
contain AA esterified at the sn-2 position. 
cPLA2α has emerged as a key enzyme in 
regulating immunoinflammatory reactions, by 
catalyzing receptor-coupled AA mobilization 
and attendant eicosanoid biosynthesis [3, 4]. 
As a consequence, cPLA2α has been shown to 
play pivotal roles in several physiological 
processes, ranging from parturition to bone 
resorption, as well as being involved in 
inflammation and in pathological processes 
such as arthritis, brain injury, and airway 
injury [3, 4]. 
 Recently, roles for cPLA2α have been 
suggested in mediating different types of cell 
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death by various agents, particularly oxidant 
substances [5-7]. However discrepancies exist 
and, as a matter of fact, cPLA2α has also been 
suggested to play a cytoprotective role in some 
instances [8], and even to be inactivated in 
apoptotic cells by proteolytic cleavage, thus 
playing no role in the cell death process itself 
[9, 10]. In the present work we have studied 
the role of cPLA2α during cell death induced 
by cytoplasmic Ca2+ overload by treating cells 
with the Ca2+ ionophore ionomycin. Our 
results, utilizing cells overexpressing wild-type 
cPLA2α and a cPLA2α mutant that has a 
greatly impaired ability to bind calcium, 
suggest that cPLA2α may protect cells from 
death via generation of free AA. Moreover, our 
data suggest that the extent of free AA may 
regulate the events that are ultimately 
responsible for the cells surviving or dying. 
 
 
 
EXPERIMENTAL PROCEDURES 
 
Materials - [5,6,8,9,11,12,14,15-
3H]AA (200 Ci/mmol) was purchased from 
Amersham Ibérica (Madrid, Spain). MAFP 
was from Cayman Chemical Co., Inc. (Ann 
Arbor, MI). Anti-cPLA2α and anti-caspase 3 
antibodies were from Cell Signaling 
Technology (Beverly, MA). Polyclonal anti-
caspase 9 was purchased from BD Biosciences 
Pharmingen. The general caspase inhibitor Z-
VAD-FMK and the calpain inhibitor 
PD150606 were from Calbiochem. 
Tetramethyl rhodamine methyl ester (TMRE) 
was from Molecular Probes. All other reagents 
were from Sigma. 
 
Cells - HEK cells were cultured in 
DMEM supplemented with 2 mM glutamine, 
10% fetal calf serum, 100 U/ml penicillin and 
100 µg/ml streptomycin at 37ºC in a 5% CO2 
humidified incubator. Cells were passaged 
twice a week by trypsinization. Cells (40-70% 
confluence) were transfected with 1 µg 
plasmid/ml using Lipofectamine PlusTM 
(Invitrogen), following the manufacturer’s 
instructions. For stably transfected cells, 1 
mg/ml G418 was used for selection and 
subsequent passages.  
RAW 264.7 cells were cultured in 
RPMI medium supplemented with 10% fetal 
calf serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 2 mM glutamine at 37 ºC in 
a 5% CO2 humidified incubator.  
 
Confocal microscopy - Cells were 
seeded on glass bottom culture dishes (MatTek 
Corp., Ashland, MA) coated with Poly-L-
lysine (Sigma). After 24 hours, the culture 
medium was replaced by HBSS containing 10 
mM HEPES and 1.3 mM CaCl2. Cells were 
monitored at 37°C by confocal microscopy 
using a Bio-Rad laser scanning Radiance 2100 
system coupled to a Nikon TE-2000U inverted 
microscope equipped with a DH-35 tissue 
culture dish heater (Warner Instruments). Most 
images shown in this paper were obtained with 
a CFI Plan Apo 60X, oil immersion, 1.40 NA 
objective, which provided a theoretical 
confocal layer thickness of approximately 0.4 
µm at the wavelengths used. Green 
fluorescence from the EGFP was monitored at 
488 nm argon laser excitation and the 
combination of a HQ500 long band pass and a 
HQ560 short band pass blocking filters. Red 
fluorescence from Cy3-annexin V was 
monitored at 543 nm HeNe laser excitation 
using a HQ590/570 long band pass blocking 
filter. For experiments in witch Cy3-annexin V 
was used, the cells were incubated  in a buffer 
consisting of 10 mM Hepes, 140 mM NaCl, 
2.5 mM CaCl2, pH 7.4, to allow  proper 
binding, and 1 µg/ml Cy3-annexin V was 
added 15 minutes prior to stimulation with 5 
µM ionomycin.  
 
AA release - HEK cells (2.5 x 105/well) were 
labeled with 0.25 µCi [3H]AA overnight. Cells 
were then extensively washed and overlaid 
with 0.5 ml serum-free RPMI supplemented 
with 0.5 mg/ml albumin and treated with 5 µM 
thimerosal for 15 min to blunt fatty acid 
reacylation [11]. Cells were then stimulated 
with 5 µM ionomycin for different time 
periods. Supernatants were removed and cell 
monolayers were overlayed with ice-cold 
phosphate buffer containing 0.05% Triton X-
100, and scraped with a cell scraper. Total 
lipids from supernatants and cells were 
extracted according to Bligh and Dyer [12]. 
After extraction, lipids were separated by thin-
layer chromatography using the system n-
hexane/diethyl ether/acetic acid (70:30:1 by 
volume). This system clearly separates 
phospholipid-bound AA from the one in 
free fatty acid form. Spots corresponding to 
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AA and phospholipid were scraped and 
radioactivity was quantified by liquid 
scintillation counting. 
 
Stimulated [3H]AA release represents a 
balance between what is being liberated by 
phospholipases minus what is being 
reincoporated back by the enzymes of the 
reacylation pathway.  As our assay 
includes 5 µM thimerosal to blunt fatty 
acid reacylation, the vast majority of  the 
AA liberated by the ionophore-stimulated 
PLA2 will be recovered as free fatty acid. 
This distinguishes between incorporated 
and released fatty acid.  
 
Immunoblot - Cells were lysed with 
lysis buffer, and 20-50 µg of protein was 
separated by standard 10% SDS-PAGE and 
transferred to nitrocellulose membranes. 
Primary (1:1000) and secondary antibodies 
(1:5000) were diluted in a buffer 25 mM Tris-
HCl, 140 mM NaCl, pH 7.4, with 0.5% 
defatted dry milk and 0.1% Tween 20. 
Membranes were developed by the 
chemiluminescent ECL system (Amersham). 
 
 Constructs and mutagenesis - The 
DNA sequence of human cPLA2α (Group IVA 
PLA2) was cloned into the pEGFP vector 
(Clontech, Palo Alto, CA) using Hind-III and 
Pst-I cloning sites. This construct codifies for 
the expression of a fusion protein containing 
an N-terminal EGFP followed by the entire 
sequence of the human cPLA2α (EGFP-
cPLA2). Wild type cPLA2α was mutagenized 
within the calcium-binding site by replacing 
aspartic acid in position 43 by asparagine 
(D43N) using the QuikChange XL Site-
Directed Mutagenesis kit from Stratagene  and 
the oligonucleotides  5’-
CATGCTTGATACTCCAAATCCCTATGTG
GAAC-3’ (forward) and 5’-
GTTCCACATAGGGATTTGGAGTATCAA
GCATG-3’ (reverse).  Mutagenesis was 
confirmed by sequencing.  
 
 Analysis of the mitochondrial 
membrane potential (∆Ψm) - To study ∆Ψm, 
the cells were stained with either 7.5 µM 5,5´, 
6,6´-tetrachloro-1,1´,3,3´-tetraethyl 
benzimidazol-carbocyanine iodide (JC-1), or 
20 nM tetramethyl rhodamine methyl ester 
(TMRE) for 15-20 min at 37°C. Cells were 
then detached from the culture flasks by 
pipetting, washed, and resuspended in PBS 
containing 1.3 mM CaCl2 and 1 mM MgCl2. 
The cells were analyzed in a Beckman Coulter 
flow cytofluorimeter at 37°C. Green 
fluorescence was monitored at 505-545 nm 
(FL1), and red fluorescence at 555-600 nm 
(FL2). For analysis of JC-1 fluorescence under 
the confocal microscope, the cells were plated 
in MatTeck dishes, labeled with JC-1, and 
monitored as mentioned above, using 488 nm 
argon laser excitation and the combination of a 
HQ500 long band pass and a HQ560 short 
band pass-blocking filters for the green 
fluorescence, and a HQ570 long band pass-
blocking filter for the red fluorescence. 
 Confocal microscopy measurement of 
TMRE-loaded cells was performed at 530 nm 
HeNe laser excitation using a 570 long-pass 
blocking filter. Fluorescence intensity was 
quantified in a perinuclear ring in which 
mitochondrial clusters are located.  
 
 Cell viability assay. The viability of 
cells was determined by the measurement 
of their capacity to exclude the dye Trypan 
blue. In brief, cells were cultured in 12-
well plates and incubated at 37°C in the 
absence or presence of 5 µM ionomycin 
for different time periods. After this 
incubation, the cells were gently scraped, 
pelleted by centrifugation, resuspended in 
500 µl of culture medium containing 0.2% 
Trypan blue, loaded into a hemocytometer, 
and examined by light microscopy. Viable 
and nonviable (blue cells) cells were then 
counted, and the score obtained expressed 
dead cells in percent of total cells. 
 
 Intracellular Ca2+ measurements. 
HEK cells were loaded with 3 µM Fluo-5F-
AM for 20 min in medium with 10% serum at 
37ºC in a 5% CO2 incubator. Cells were then 
washed and incubated with HBSS containing 
10 mM HEPES and 1.3 mM CaCl2. 
Fluorescence was monitored under confocal 
microscope at 488 laser excitation and the 
combination of a HQ500 long band pass and a 
HQ560 short band pass blocking filters, having 
the iris totally open. At the end of each 
experiment calibration was carried out as 
previously described by Kao et al. [13], using 
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MnSO4 at a final concentration of 2 mM, and 
lysis with 40 µM saponin to obtain the 
background signal.  
 
 
RESULTS
 
Characterization of HEK cells 
overexpressing cPLA2α and the mutant D43N-
cPLA2. Transfection of HEK cells with the 
construct EGFP-cPLA2α resulted in an 
elevated AA response to the calcium 
ionophore ionomycin, as compared with wild 
type-untransfected cells (Fig. 1A). In contrast, 
cells transfected with a cPLA2α mutant in 
which Asp43 was replaced with Asn (EGFP-
D43N-cPLA2α) [14-16], did not reproduce the 
increased AA mobilization. This was to be 
expected, since such a mutation greatly impairs 
the ability of cPLA2α to interact with the 
membrane in a Ca2+-dependent manner [14-
16]. Fig. 1B shows that overexpression of 
EGFP-cPLA2α or its D43N mutant in the HEK 
cells resulted in a robust expression of the 
fusion proteins, as judged by immunoblot. 
Wild type EGFP-cPLA2α was 
distributed uniformly throughout the 
cytoplasm of resting HEK cells (Fig. 1C). 
Shortly after ionomycin stimulation, EGFP-
cPLA2α translocated first to perinuclear 
structures that may represent the Golgi and 
endoplasmic reticulum (Fig. 1C, 5-8 min), and 
later to the nuclear envelope (Fig. 1C, 10-30 
min). This is in agreement with recent data by 
others [17]. These localization changes were 
not observed in cells expressing EGFP only 
(data not shown). The time course of EGFP-
cPLA2α translocation is consistent with the 
observed time course of AA release in these 
cells, supporting the notion that binding to 
intracellular membranes is an essential step in 
cPLA2α activation. In contrast with the above, 
the mutant, EGFP-D43N-cPLA2α did not 
translocate to perinuclear membranes 
following ionomycin addition. 
It is noteworthy that cells transfected 
with the EGFP-D43N- cPLA2α but not those 
transfected with EGFP-cPLA2α exhibited 
notable morphological changes after 
ionomycin treatment. We consistently 
observed the appearance of vacuole-like 
structures (black areas under the microscope), 
as well as increased nuclear fluorescence, 
which probably reflects increased nuclear 
permeability (Fig. 1D). Since both kinds of 
changes are known to accompany cell death in 
different cell systems, we sought to 
characterize the ionomycin-induced HEK cell 
death, and the intriguing role of cPLA2α in this 
process.  
 Analysis of Ca2+-dependent death in 
HEK cells. Measurement of the intracellular 
Ca2+ level in cells revealed a very rapid rise 
from ~100 nM in untreated cells to about 4 µM 
in the ionomycin-treated cells, reflecting 
cytoplasmic calcium overload (Fig. 2A). No 
differences in the kinetics or amplitude of 
calcium overload were found among wild type 
and cells transfected with plasmids encoding 
for cPLA2α or the mutant D43N-cPLA2. To 
assess whether the overload of Ca2+ is the 
cause or a consequence of cell death, viability 
experiments were conducted in cells exposed 
to ionomycin in the absence or presence of 
extracellular Ca2+. Ionomycin-induced death 
only occurred if the incubation media 
contained Ca2+, thus providing clear evidence 
that cell death is caused by cytoplasmic Ca2+ 
overload (Fig. 2B). 
 The effect of cPLA2α overexpression 
on cell death was assayed next, and the results 
are shown in Fig. 2C. Wild type cells 
underwent massive death when exposed to 
ionomycin (over 70% of the cells died after 1-
2 h exposure to ionomycin). In contrast, cell 
death in the cPLA2α-transfected cells was kept 
consistently lower, even after 3 h incubation 
with the ionophore. These data provide direct 
evidence that cPLA2α protects cells from Ca2+ 
overload-induced death.   
In non transfected HEK cells 
ionomycin induced a modest release of AA 
and also morphological changes similar to 
those observed in the EGFP-D43N-cPLA2α 
transfected cells. Some of these changes, i.e. 
cellular shrinking, and nuclear shape 
alterations, could be easily visualized under 
bright field microscopy (Fig. 3A).  
It is well described that mitochondrial 
membrane potential (∆Ψm) changes, 
externalization of anionic phospholipids such 
as phosphatidylserine, activation of caspases, 
and chromatin condensation are all events 
related with programmed cell death [18, 19]. 
Changes in ∆Ψm were studied by loading HEK 
cells with the ratiometric indicator JC-1, that 
selectively accumulates in the mitochondria 
(monomers, green florescence, low membrane 
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potential), and subsequently aggregates as a 
function of ∆Ψm (red fluorescence, high 
membrane potential). Control untreated HEK 
cells loaded with JC-1 exhibited a 
heterogeneous distribution of depolarized 
(green) and hyperpolarized (red) mitochondria 
(Fig. 3B), as visualized by confocal 
microscopy. However, ionomycin-treated cells 
only showed green fluorescence, presumably 
due to a diffusion of JC-1 into the cytosol 
following depolarization of mitochondria. This 
process was also evaluated by flow cytometry, 
which is a more quantitative technique (Fig. 
3C). Again, cells treated with ionomycin 
experienced an increase in green fluorescence 
and a decrease in red fluorescence. The 
mitochondrial uncoupler p-
trifluoromethoxycarbonyl cyanide 
phenylhydrazone (FCCP), which induces 
mitochondria depolarization [20], produced  
fluorescence changes similar to that of 
ionomycin (data not shown). 
Mitochondria depolarization can 
precede caspase activation, especially that of 
caspase-9, an initiator caspase that is 
proteolytically activated by binding to 
cytochrome c, after the latter is released from 
the mitochondria. Figure 3D indicates that 
ionomycin-treated cells showed no appearance 
of active fragments of caspase-9, except at 
very long times (i.e. >8 h). No active 
fragments of the effector caspase-3 could be 
detected at any time (Fig. 3D).  
Chromatin condensation was analyzed 
by nuclear staining with the DNA-binding 
fluorophore (DAPI). By this procedure, no 
signs of chromatin condensation were detected 
at any time after ionomycin treatment of the 
cells (data not shown). 
Externalization of phosphatidylserine 
is an event that parallels some types of cell 
death, and it can be easily detected by 
analyzing the binding of fluorescent annexin V 
to the cellular surface [21]. Cells treated with 
ionomycin for 10 min showed staining of the 
outer cellular surface with Cy3-annexin V, 
thus suggesting externalization of 
phosphatidylserine (Fig. 4A). Increased 
annexin V binding to the cells was not 
observed if the cells were treated with the 
general inhibitor Z-VAD-FMK, suggesting the 
involvement of caspases and/or calpains [22] 
(Fig. 4B).  
The involvement of caspases in 
phosphatidylserine externalization can be ruled 
out by the data of Fig. 3D, where the lack of 
appearance of active mitochondria-related 
caspases-3 and -9 was shown. Therefore, 
experiments were conducted to study the 
possible involvement of calpains under those 
conditions. HEK cells preincubated with the 
specific calpain inhibitor PD150606 blocked 
annexin-V labeling after 15 min of ionomycin 
treatment (Fig. 4C), whereas the negative 
control PD145305 did not (data not shown). 
These data confirmed the involvement of 
calpains in phosphatidylserine externalization 
in this system. Control experiments adding 
EGTA to the incubation medium confirmed 
the Ca2+-dependent nature of the ionomycin-
induced phosphatidylserine externalization 
(data not shown). 
 
EGFP-cPLA2α overexpression 
prevents phosphatidylserine exposure in 
response to ionomycin. Initial experiments had 
shown that ionomycin induced morphological 
changes in the mutant EGFP-D43N-
cPLA2α  οverexpressing cells were not present 
in the wild-type EGFP- cPLA2α-
overexpressing cells (Fig. 1), and also that 
cPLA2α protected cells for Ca2+ overload-
induced death (Fig. 2C). Next, we investigated 
whether these differences correlated with 
phosphatidylserine externalization. Cells 
overexpressing EGFP-cPLA2α did not show 
increased exposure of phosphatidylserine in 
response to ionomycin treatment, as judged by 
annexin V staining (Fig. 5A). Interestingly, in 
cells overexpressing the calcium-binding 
domain mutant EGFP-D43N- cPLA2α, 
labeling of the outer cellular surface with 
annexin V was detected (Fig. 5B). The images 
taken from mutant EGFP-D43N-cPLA2α-
transfected cells showed that treatment with 
ionomycin not only increased their intranuclear 
fluorescence but also induced cellular 
membrane blebbing (Fig. 5B), which is 
another striking early feature of some types of 
cell death [23].    
  
 Specific inhibition of cPLA2α activity 
abrogates the protective effect of cPLA2α 
overexpression. To further demonstrate that 
the cPLA2α protective role is dependent upon 
its enzymatic activity, experiments were 
conducted in the presence of the active site-
directed cPLA2α inhibitor methyl arachidonyl 
fluorophosphonate (MAFP) [24]. Control 
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experiments indicated that treating the cells 
with 10 µM MAFP for 30 min completely 
abrogates cellular Ca2+-dependent PLA2  
activity, as judged by an in vitro assay [25]. 
Figure 6 shows that MAFP did not inhibit the 
translocation of EGFP-cPLA2α to perinuclear 
membranes in the ionomycin-treated cells; 
however, these cells were very strongly labeled 
with annexin V (Fig. 6). This behavior is 
similar to the one described above in wild type 
HEK cells or in cells transfected with the 
mutant D43N-cPLA2α, and clearly shows that 
the activity of the cPLA2α is needed for the 
enzyme to exert an effect.  
 
Effect of exogenous AA. To further 
characterize cPLA2α overexpression in these 
cells, we next investigated whether any of the 
putative products of cPLA2α action on 
phospholipids, namely free AA and 
lysophospholipid, could mimic the effect of 
cPLA2α overexpression on the HEK cells. The 
results are shown in Fig. 7, and demonstrate 
that addition of micromolar levels of free AA 
prior to treatment with ionomycin prevented 
phosphatidylserine externalization, as judged 
by Cy3-annexin V plasma membrane labeling. 
Importantly, the effect of free AA was found to 
be specific, as neither lysophosphatidylcholine 
nor other fatty acids like palmitic acid 
prevented phosphatidylserine externalization 
after ionomycin treatment (Figure 7). 
 
AA induces ∆Ψm changes in HEK 
cells. Free fatty acids have been shown to 
directly act on the mitochondria by increasing 
proton permeability, opening the mitochondrial 
permeability transition pore [26], and/or 
influencing the activity of mitochondrial 
uncoupling proteins [27]. Since either of these 
actions would have an effect on ∆Ψm, we 
studied whether AA changes the mitochondrial 
potential of HEK cells. JC-1 labeled HEK cells 
were analyzed by flow cytometry. As shown in 
figure 8, exogenous free AA produced a rapid 
and robust increase in JC-1 green fluorescence 
(within the first 5 min of treatment), while 
palmitic acid, a fatty acid that does not induce 
phosphatidylserine externalization (Fig. 7), had 
no effect, either if added alone, before or after 
AA. The mitochondrial uncoupler FCCP,  
produced a fluorescence increase similar to 
that of AA (not shown). 
 
Overexpression of EGFP-cPLA2α 
changes mitochondrial polarization after 
ionomycin treatment of HEK cells. It has been 
described that ∆Ψm is the driving force for 
mitochondrial Ca2+ overload [28]. Thus, the 
above results would suggest that, after 
ionomycin treatment, the high levels of AA 
produced in the EGFP-cPLA2α transfected 
HEK cells may act to change ∆Ψm and, hence, 
inhibit mitochondrial calcium uptake and 
overload. The ultimate consequence would be 
that further mitochondrial damage would not 
take place. 
To experimentally validate the above 
sequence of events, we proceeded to analyze 
∆Ψm changes in the EGFP-cPLA2α transfected 
HEK cells. Since EGFP-cPLA2α expressing 
HEK cells display green fluorescence, it was 
not possible to use JC-1. We used instead a red 
reversible potentiometric fluorescence dye, 
TMRE that preferentially accumulates in the 
mitochondria [29]. During the course of these 
experiments we noticed that the EGFP- 
cPLA2α transfected HEK cells were composed 
of two populations with varying degrees of 
EGFP-cPLA2α expression, as judged by flow 
cytometry (Fig. 9). To compare wild type and 
EGFP-cPLA2α overexpressing cells within the 
same experiment, we took advantage of the 
fact that in flow cytometry it is possible to 
separately analyze populations that exhibit a 
distinct fluorescent pattern. We mixed wild 
type cells –exhibiting green autofluorescence 
only--, with EGFP-cPLA2α overexpressing 
cells, --exhibiting low and high green 
fluorescence--, and labeled them all with 
TMRE.  Analysis of red fluorescence (TMRE 
fluorescence) in each single population was 
then performed by flow cytometry. The results 
are shown in Figure 9, and indicate that, after 
ionomycin challenge, there is a rapid decrease 
in red fluorescence. However, wild type cells 
had a deeper and quicker decrease in 
fluorescence than the EGFP-cPLA2α-
transfected cells. Maximum decrease was 
observed at about 2 min after ionomycin 
treatment for wild type HEK cells, but EGFP-
cPLA2α transfected cells demonstrated a 
slower kinetics, reaching the plateau at about 5 
min after ionomycin treatment (Fig. 9B). 
Moreover, the high-expressing EGFP-cPLA2α 
population experienced the lowest changes in 
TMRE fluorescence, as compared with the 
low-expressing EGFP-cPLA2α, and wild type 
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cells. Those decrements of mitochondrial 
fluorescence primarily reflected mitochondrial 
depolarization, as further confirmed by the use 
of FCCP. The latter compound decreased 
TMRE fluorescence to an extent comparable to 
that induced by ionomycin (data not shown). 
Collectively, these data highlight the 
correlation between the amount of EGFP- 
cPLA2α expressed by the cells and the degree 
of mitochondrial depolarization after 
ionomycin treatment.  
In agreement with the above 
observations, pretreating the cells with the 
cPLA2α inhibitor MAFP potentiated the 
TMRE fluorescence decrease provoked by 
ionomycin in the three cell populations 
analyzed (Fig. 10).  
 Confocal microscopy experiments 
were also performed in the TMRE-loaded 
cells. Fig. 11A shows that mitochondria did 
exhibit significant, bright staining with TMRE. 
No other cellular compartment incorporated 
the probe at least at detectable levels. By 
measuring fluorescence intensity only from the 
perinuclear ring where mitochondrial clusters 
are located, a time-dependent decrease in 
fluorescence in response to ionomycin was 
detected Collectively, these results from 
TMRE confocal microscopy (Figs. 11B & 
11C), are fully consistent with the TMRE flow 
cytometry measurements described above 
(Figs. 9 and 10). 
 
 Studies with RAW 264.7 macrophages. 
To study whether the protective effect of AA 
on Ca2+ overload-induced cell death is a 
general one, we conducted studies with the 
murine macrophage-like cell line RAW264.7. 
These cells showed increased surface 
appearance of phosphatidylserine in response 
to inomycin, as judged by Cy3-annexin V 
staining (Fig. 12). Importantly, pretreating the 
cells with exogenous AA prevented the surface 
staining with Cy3-annexin V (Fig. 12). 
 To assess whether cPLA2α has similar 
cytoprotective effects under more 
physiological conditions, we studied the effect 
of cPLA2α overexpression on the cell death 
response of RAW 264.7 macrophage-like cells 
to peroxynitrite. Peroxynitrite, the coupling 
product of nitric oxide and superoxide, is 
thought to play a pivotal role in eliciting tissue 
damage during inflammation [30]. Exposure of 
RAW264.7 to 500 µM peroxynitrite for 1 h 
resulted in 40 ± 5% of the cells being positive 
for Trypan blue staining. Interestingly, in cells 
overexpressing cPLA2α, the percentage of 
cells positive for Trypan blue under exact 
experimental conditions was lowered down to 
12 ±3. 
 
 
 
  
 
DISCUSSION 
 
 
Previous studies have demonstrated 
that cPLA2α is the key effector involved in 
stimulated AA mobilization in response to 
Ca2+ ionophores [31, 32], and the results 
reported in this study are consistent with these 
previous observations. The response of EGFP-
cPLA2α transfected HEK cells to the Ca2+ 
ionophore ionomycin is very rapid, linearly 
increasing up to 15 min of exposure of the 
drug to the cells, and reaching a plateau 
thereafter. Under these conditions, cell death 
became apparent as early as 15 min after 
addition of ionomycin to the cells, as judged 
by increased blebbing, nuclear protrusion and 
permeability, as well as exposure of anionic 
aminophospholipids on the cell surface. These 
data are generally consistent with previous 
reports on the effects of cytoplasmic Ca2+ 
overload on early cell death, but they also 
provide important insights on to the role of 
cPLA2α-derived free AA levels as regulators 
of the balance between cell survival and death. 
 
We have found that overexpression of 
cPLA2α in HEK cells, results in the cells being 
protected from ionomycin-induced early 
signals of cell death. Importantly, this 
protective effect is not observed in cells 
overexpressing a cPLA2α mutant in which the 
Asp43 has been replaced with Asn. Such a 
mutation causes the enzyme not to translocate 
to intracellular membranes in response to Ca2+ 
elevations, making it unable to reach its 
substrate and thus catalyze phospholipid 
hydrolysis [14-16].   
 
The above data strongly suggested that 
the pro-survival effect of cPLA2α documented 
in this work is caused by the elevated 
formation of a metabolite derived from the 
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action of cPLA2α on phospholipids, namely 
free AA or a lysophospholipid. This prompted 
us to analyze the effect of treating the cells 
with low micromolar doses of free AA or 
lysophosphatidylcholine during ionomycin-
induced cell death. The results indicate that 
only free AA exerts an effect. Interestingly, 
palmitic acid, at the same concentrations used 
for AA, fails to protect the cells, a finding that 
is consistent with the well known fact that 
cPLA2α exhibits striking specificity for AA-
containing phospholipids [1]. 
  
Our results appear to be in line with 
those studies that have suggested that, when 
cells commit to die in response to death 
ligands such as tumor necrosis factor α or Fas 
ligand, an early cellular event is the proteolytic 
cleavage of cPLA2α by caspases to prevent 
liberation of AA and its subsequent 
metabolism to eicosanoids [9, 10]. It is inferred 
from these results that cPLA2α activation may 
help promote cell survival under certain 
conditions. Similarly, it has also been 
suggested that PLA2s may function to remove 
phospholipids damaged by or during the death 
process, thus allowing membrane repair and 
helping promote cell survival [33]. Our 
observation that not only cPLA2α per se but 
also micromolar levels of exogenous AA are 
cytoprotective for ionomycin-treated HEK 
cells suggests that the fatty acid itself may be 
involved in a pathway leading to cell survival.  
  
In keeping with the above we 
characterized further the protective mechanism 
mediated by AA. We observed that 
micromolar concentrations of free AA induce 
mitochondrial depolarization. It is unlikely that 
such elevated free AA levels are reached 
during ionomycin stimulation of the cells, even 
those overexpressing cPLA2α. Free AA being 
released upon ionophore stimulation would 
therefore induce smaller changes in ∆Ψm than 
those induced by exogenous, micromolar 
levels of AA. Such an effect could be produced 
by at least three different routes, namely (i) 
AA acting as a mitochondrial protonophore, 
(ii) AA opening the mitochondrial 
permeability transition pore, or (iii) AA acting 
on uncoupling proteins. The latter possibility 
appears unlikely in view of the lack of an 
effect of palmitic acid on HEK cell 
depolarization, for palmitic acid is known to be 
an effective activator of uncoupling 
mitochondrial proteins [33]. 
 
Given that accumulation of Ca2+ into 
the mitochondria is driven by the ∆Ψm, [28] it 
can be concluded from our data that, in the 
overexpressing-cPLA2α HEK cells, ionomycin 
will induce both Ca2+ entry into the 
mitochondria and the release of high amounts 
of AA via cPLA2α activation. Intracellular AA 
would then produce small changes in ∆Ψm, and 
blunt the capture of Ca2+ by this organelle. 
Then, complete dissipation of ∆Ψm that usually 
takes place after mitochondrial Ca2+ overload 
would not take place. As an ultimate 
consequence, mitochondrial damage would 
cease, and the subsequent events that parallel 
cell death, i.e. phosphatidylserine 
externalization, are stopped or delayed.  
 
Collectively, our work leads to the 
important conclusion that high levels of free 
AA derived from cPLA2α activation may play 
a cytoprotective role in cells exposed to a 
cytoplasmic Ca2+ overload.  It is noteworthy 
that the mode of cell death induced by Ca2+ 
ionophores has been related to both their 
chemical nature as well as the concentrations 
utilized, lower concentrations causing 
apoptosis and higher concentrations causing 
necrosis in some cell types [35, 36]. In 
between these two extremes, it has also been 
reported that in certain cells, Ca2+ overload 
may produce cell death with characteristics of 
both necrosis and apoptosis [37]. Consistent 
with the latter, in the cell death system 
described here there is a very rapid 
mitochondrial depolarization, externalization 
of phosphatidylserine, blebbing, nuclear shape 
changes and increased nuclear permeability. 
All of these events occur during the first 15-30 
min after ionomycin treatment, and most of 
them are typical of cells committed to 
apoptotic death. At longer times, there is 
neither caspase activation nor nuclear 
chromatin condensation, and these are 
processes more consistent with a necrotic type 
of death.  
 
Of special relevance to the results 
presented in this work is a recent study by 
Tommasini et. al. [8] in peroxynitrite-treated 
U937 cells. These authors found that cPLA2α 
activation promoted survival in cells exposed 
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to peroxynitrite and the effect was mediated by 
free AA. By utilizing different maneuvers to 
decrease the activation state of the cPLA2α and 
the capacity of the cells to generate AA, (i.e. 
chemical inhibitors, antisense 
oligonucleotides) Tommasini et. al. [8] made 
the key observation that the extent of AA 
formation regulates the balance between cell 
survival and death.  By means of a different 
experimental approach (i.e. increasing the 
cellular levels of cPLA2α activity by 
overexpressing the enzyme), we have obtained 
results that are in agreement with the work by 
Tommasini et. al. [8]. It appears therefore that 
the cytoprotective effect of elevated levels of 
free AA is not restricted to the context of Ca2+-
dependent cell death, but may operate in other 
settings as well, such as triggering of cell death 
after an oxidative insult. As a matter of fact, 
we have obtained evidence that overexpression 
of cPLA2α in RAW264.7 macrophages also 
prevents peroxynitrite-induced cell death. 
 
On the other hand, there are a number 
of reports suggesting that free AA and cPLA2α 
activation may act to favor cell death under a 
variety of settings. For example, tumor 
necrosis factor-α mediated apoptosis is 
impaired in cells deficient in cPLA2α [38] or 
when the enzyme is inhibited by 
pharmacological means [39]. Inhibition of AA 
metabolizing enzymes results in elevated AA 
levels which has been related to apoptosis 
[40,41], and the proapoptotic effects have also 
been reproduced by direct addition of 
exogenous fatty acid in some instances [42]. 
Moreover, overexpression of either long chain 
fatty acyl-CoA synthetase or cyclooxygenase-
2, --which scavenge free AA by converting it 
into the CoA thioester derivative or 
prostaglandin, respectively--, protects cells 
from apoptosis [43]. These results are 
consistent with the proposed proapoptotic 
effects on nonsteroidal anti-inflammatory 
drugs under certain conditions [44]. In rat 
hepatoma MH1C1 cells, it was shown that free 
AA increases upon stimulation of cPLA2a by 
the ionophore A23187 and causes cell death 
through the mitochondrial pathway [6].  
Clearly, the role of cellular free AA acid on 
apoptosis is a debatable issue, and appears 
to be strikingly dependent on experimental 
conditions and agonists under study. 
 
From a pathophysiological point of 
view, the overexpression of cPLA2α resulting 
in enhanced cell survival may bear important 
consequences with regard to mammalian cell 
defense against virus infection. In a recent 
report, Allal et. al. [45] have found that 
cPLA2α is one of the several host-derived 
proteins carried by human cytomegalovirus. 
Although the function of these host-cell 
derived proteins is mostly unknown, 
cPLA2αhas been suggested to be required for 
proper infectivity [46, 47]. Based on our data 
demonstrating that overexpression of 
cPLA2α protects from cell death, it is tempting 
to speculate that a critical function of the 
cPLA2α borne by the human cytomegalovirus 
and injected into the host cell may be that of 
ensuring survival of the infected cell by 
maintaining free AA at high levels. In this 
manner, the execution of the host cell’s death 
program would be blocked and the virus would 
buy the time necessary to fully replicate inside 
the host cell.  
In conclusion, our data demonstrate 
that overexpression of cPLA2α in HEK cells 
protects them from death induced by 
cytoplasmic Ca2+ overload, and that the 
mechanism involves the generation of elevated 
levels of free AA, and changes in ∆Ψm. Since 
the cPLA2α ordinarily present in wild type 
cells appears not to produce AA at high 
enough levels to counteract the early death 
induced by ionomycin, it appears that under 
conditions of Ca2+ overload, it is the extent of 
free AA availability that determines whether 
the cell will survive or die. 
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FIGURE CAPTIONS 
 
Figure 1. [3H]AA release and cPLA2 translocation in HEK cells. A) Wild type HEK cells, 
cells transfected with EGFP-cPLA2α, and cells transfected with the mutant EGFP-D43N-cPLA2α 
were labeled overnight with [3H]AA as described under Experimental Procedures. The cells were then 
stimulated with 5 µM ionomycin for the indicated periods of time, and [3H]AA release was analyzed 
by thin-layer chromatography. The data are expressed as percent of total label incorporated in 
phospholipids. B) Cell lysates from wild type HEK cells, EGFP-cPLA2α−transfected HEK cells, 
EGFP-D43N-cPLA2α transfected HEK cells or RAW 264.7 cells were analyzed by immunoblot using 
specific antibodies against cPLA2α. C, D) HEK cells, transfected with EGFP-cPLA2α (C) or the 
mutant EGFP-D43N- cPLA2α (D), were stimulated with 5 µM ionomycin and images were recorded 
under confocal microscopy at the indicated times. [3H]AA release measurements were carried out in 
triplicate and a representative experiment out of three is shown. Confocal experiments were done at 
least four times and many cells were analyzed each time. 
 
Figure 2. Calcium dependence of cell death. A) Wild type (closed circles), cPLA2α-
transfected (open circles), or D43N-cPLA2α-transfected HEK cells (close triangles) were loaded with 
fluo-5F-AM, and intracellular calcium measurements were performed. The arrow indicates the time at 
which 5 µM ionomycin was added to the cells. For these experiments cells expressing cPLA2αs 
withou EGFP were used so as to avoid interference with the fluo-5F fluorescence.  B) Wild type 
(circles) or EGFP-D43N-cPLA2α transfected HEK cells (triangles) were treated with 5 µM ionomycin 
in the absence (open simbols) or presence (closed simbols) of 1.3 mM CaCl2 in the incubation 
medium. After the indicated times, cell viability was assessed by Trypan Blue exclusion. C) Wild type 
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(open bars) or cPLA2α-overexpressing (closed bars) HEK cells were treated with 5 µM ionomycin for 
the indicated periods of time. Afterward, cell viability was assessed by Trypan Blue exclusion. 
 
Figure 3. Cellular changes induced by ionomycin. Wild type HEK cells were treated with 5 
µM ionomycin or vehicle for the indicated periods of time, and analyzed for A) changes in cell shape 
under bright field microscopy; B) JC-1 staining observed by confocal microscopy; C) JC-1 staining 
studied by flow cytometry (left panel, green fluorescence; right panel, red fluorescence); D) the 
presence of active fragments of caspase-9 and caspase-3 by immunoblot. As a control to visualize 
active caspases Jurkat cells treated with Camptothecin were used (Camp, panel D, first lane from the 
right). Experiments were carried at least three times, and representative experiments are shown. 
 
Figure 4. Ionomycin induces Cy3-annexin V binding to HEK cells. HEK cells were 
preincubated with Cy3-annexin V (1 µg/ml) for 15 min in the absence (Control) or presence of the 
general caspase/calpain inhibitor Z-VAD-FMK (A) or the specific calpain inhibitor PD156060 (20 
µM) (B). Cells were then stimulated with 5 µM ionomycin for 10 min. Confocal microscopy images 
were taken before and after ionomycin treatment. Experiments were done at least thrice, and many 
cells were analyzed in each experiment. 
 
Figure 5. cPLA2α overexpression prevents ionomycin-induced Cy3-annexin V binding. HEK 
cells transfected with EGFP-cPLA2α (A) or the EGFP-D43N- cPLA2α mutant (B) were preincubated 
with 1 µg/ml Cy3-annexin V for 15 min and then stimulated with 5 µM ionomycin for 10 min. Cells 
were monitored by confocal microscopy and pictures were taken before and after ionomycin 
treatment. Experiments were done at least three times, and many cells were analyzed in each 
experiment. 
 
Figure 6. Annexin V labeling of cPLA2a-overexpressing cells treated with MAFP. HEK cells 
transfected with EGFP-cPLA2 were preincubated with 1 µg/ml Cy3-annexin V for 15 min in the 
absence (A) or presence of the cPLA2 inhibitor MAFP (10 µM) (B). Cells were then stimulated with 5 
µM ionomycin for 10 min, observed by confocal microscopy and pictures were taken at the indicated 
time points. Experiments were done at least three times, and many cells were analyzed.  
 
Figure 7. Exogenous AA prevents ionomycin-induced Cy3-annexin V in HEK cells. HEK cells 
were preincubated with 1 mg/ml Cy3-annexin V for 15 min in the absence (A) or presence of 10 µ M 
AA (B), lysophosphatidylcholine (10 µM) (C), or palmitic acid (10 µM) (D). Cells were then 
stimulated with 5 µM ionomycin. Fluorescence was monitored by confocal microscopy and images 
were taken before and after 10 min ionomycin stimulation. Experiments were done at least three times, 
and many cells were analyzed. 
 
Figure 8. Time-course of JC-1 fluorescence changes in HEK cells. Wild type HEK cells were 
labeled with 7.5 µM JC-1 for 15 min, and analyzed for changes in JC-1 fluorescence by flow 
cytometry as described in Experimental Procedures. At the indicated time points 10 µM palmitic acid 
or 10 µM AA was added to the cells. Experiments were done at least three times and fluorescence 
from 50-100 x 103 cells was analyzed each time. 
 
Figure 9. Time-course of TMRE fluorescence changes in wild type and two populations of 
EGFP-cPLA2α-expressing HEK cells. (A) Green fluorescence was analyzed by flow cytometry in wild 
type (light grey) and EGFP-cPLA2α−transfected HEK cells (dark grey). (B) HEK cells, and the two 
populations of EGFP- cPLA2α−expressing cells were mixed, labeled with 20 nM TMRE and red 
fluorescence was monitored by flow cytometry. 5 µM ionomycin was added to the medium at the 
indicated time points. After data collection red fluorescence was analyzed for each population 
separately. Experiments were done at least three times and fluorescence from 50-100 x 103 cells was 
analyzed each time. 
 
 14
Figure 10. Effect of MAFP on TMRE fluorescence in ionomycin-treated HEK cells. Wild type 
and EGFP- cPLA2α transfected HEK cells were labeled with 20 nM TMRE, and treated with vehicle 
or 10 µM MAFP for 10 min. Red fluorescence was monitored by flow cytometry. 5 µM Ionomycin 
was added at the indicated time points. After data acquisition, analysis of red fluorescence was done 
separately for each population of cells: A) wild type, B) low EGFP-cPLA2α−expressing HEK cells, 
and C) high EGFP-cPLA2α−expressing cells. Experiments were done at least three times and 
fluorescence from 50-100 x 103 cells was analyzed each time.  
 
Figure 11. Confocal microscopy analysis of TMRE-loaded  cells. HEK cells were loaded with 
20 µM TMRE, and analyzed under the confocal microscope (A). The cells were treated with vehicle 
(open circles) or 5 µM ionomycin (closed circles) and fluorescence was analyzed every 15 s (B). The 
transmission images  and TMRE fluorescence of the analyzed cells at 0 and 15 min after ionomycin 
treatment is shown in panel C. 
 
Figure 12. Binding of Cy3-annexin V to RAW 264.7 cells treated with ionomycin.  RAW 
264.7 cells were preincubated with 1 mg/ml Cy3-annexin V for 15 min in the absence (A) or presence 
of 10 µM AA  (B). Cells were then stimulated with 5 µM ionomycin. Fluorescence was monitored by 
confocal microscopy and images were taken before and after 10 min ionomycin stimulation. 
Experiments were done at least twice and many cells were analyzed each time. 
 15
 
 
Figure 1 
 16
Time (min)
0 30 60 90 120 150 180
Tr
yp
an
 B
lu
e-
st
ai
ne
d 
C
el
ls
 (%
)
0
25
50
75
100
Time (min)
Tr
yp
an
 B
lu
e-
st
ai
ne
d 
C
el
ls
 (%
)
0
25
50
75
100
30                         60                        120
A
B
C
Time (min)
0 5 10 15 20 25 30 35 40
[C
a2
+ ]
i (
µM
)
0.0
0.2
0.4
2.0
3.0
4.0
A
      5      0      5      10 0      5      1
Figure 2 
 17
  
 
 
 
Figure 3 
 18
 
 
 
 
 
 
 
 
Figure 4 
 19
  
 
 
 
Figure 5 
 20
 
 
 
 
 
Figure 6 
 21
 
 
  
 
 
Figure 7 
 22
  
 
 
 
 
 
Figure 8 
 23
 
 
 
 
Figure 9 
 24
 
 
 
Figure 10 
 25
 
 
Figure 11 
 26
 Figure 12 
 27
